Previous Frame Next Frame
  • Discover: How Intrexon
    is creating the code for a
    healthier planet

    World Demand
  • Intrexon Energy Partners to
    Generate High-value Oil Products
    from Low-Cost Natural Gas

    DISCOVER

    Intrexon Energy Partners to Generate High-value Oil Products from Low-Cost Natural Gas
  • Optimizing therapeutics production:
    Improving the way we generate active pharmaceutical ingredients

    DISCOVER

    Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Intrexon and Johnson & Johnson to
    advance new hair and skin products

    DISCOVER

    Johnson & Johnson Innovation
  • Next-generation fertility solutions

    DISCOVER

    OvaScience
  • World Demand
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Johnson & Johnson Innovation
  • OvaScience

UltraVector® platform to power the next generation of bio-based products
LEAP® automated purification of high value cells
RheoSwitch® precisely controlled expression
IN THE SPOTLIGHT
HEALTH
Collaboration:
Ziopharm and Intrexon are on the path to treating melanoma
FOOD
Extreme Weather:
Drought and the need for novel food applications
ENERGY
Engineering Energy:
Fueling the world with microbes
LATEST NEWS
Intrexon Prices Public Offering of Common Stock
GERMANTOWN, Md., Jan. 21, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has priced its previously announced underwritten public offering of common stock consisting of 3,750,000 shares at a public offering price of $27.00 per share.  Gross proceeds to Intrexon from this offering are expected to be approximately $101.25 million and Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as for strategic acquisitions or investments. Intrexon has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock offered in the public offering.  All of...
Intrexon Announces Proposed Public Offering of Common Stock
GERMANTOWN, Md., Jan. 20, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today it has commenced an underwritten public offering of up to $150 million of shares of its common stock.  Intrexon intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of the common stock offered in the public offering.  All of the shares in the offering will be sold by Intrexon. J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering.  Jefferies is acting as a lead manager for the offering. Griffin Securities and Mizuho Securities are acting as co-managers for the offering. The off...
Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact
Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies Combined Technologies to Leapfrog Clinical Pipeline of Next Generation Therapies Using Synthetic and Personalized Immunology GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ: ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the ...